# A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

> **NCT06974734** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Non Small Cell Lung
- Carcinoma, Pancreatic Ductal
- Malignant Melanoma
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)

## Interventions

- **DRUG:** PF-08046037
- **DRUG:** sasanlimab

## Key facts

- **NCT ID:** NCT06974734
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-05-06
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-03-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974734, "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06974734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*